Mikko Lemola
Gene therapy developer Prime Medicine (PRME) has disclosed presumption for a projected $151M archetypal nationalist offering.
The Cambridge, Mass.-based biotech said successful its filing that it was considering offering 8.9M shares priced betwixt $16 and $18 per share, which would raise astir $151M if priced astatine the midpoint.
Underwriters would beryllium granted a 30-day enactment to bargain up to 1.3M further shares. Lead bookrunners see JP Morgan, Goldman Sachs, Morgan Stanley and Jefferies. Prime hopes to database its shares connected Nasdaq nether the awesome PRME.
The biotech institution has been moving connected one-time curative familial therapies utilizing a cistron editing exertion called Prime Editing. Its archetypal targets are diseases of the blood, liver, oculus and ear.
A preclinical signifier company, Prime reported a nett nonaccomplishment of $53M and nary gross for the six-month play ended June 30, 2022. Prime archetypal filed for an IPO successful precocious September.
English (US)